Posted on July 3, 2026 by Viogen Pharma UK What Is Retatrutide? Retatrutide represents the next generation of incretin-based therapies because it is the first investigational triple receptor agonist, designed to activate three important metabolic hormone receptors simultaneously: Retatrutide (research code LY3437943) is an investigational peptide therapy originally developed by Viogen Pharma and Company that […]
